Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:05 13/03/2026 GMT			5-day change	1st Jan Change
2,031.00 ^GBX	0.00%		-0.34%	+11.32%

03-13	GSK and Amgen to add medicines to TrumpRx, Fox Business reports	RE
03-13	GSK plc Announces Expansion of AREXVY Approval to Adults Aged 18 to 49 Years for RSV Prevention	CI

Press Releases

03-13	GlaxoSmithKline Egypt profit rises 22.5% y/y to $4.07mn in 2025	AQ
03-13	GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk	BU
03-13	GSK : RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk	PU
03-10	GSK : tops Antimicrobial Resistance (AMR) Benchmark Report	PU
03-09	GSK : and Alfasigma announce agreement on worldwide rights for linerixibat	PU
03-05	GSK : Governance And Remuneration Report 2025	PU
03-05	GSK : Responsible Business Report 2025	PU
03-05	GSK : Cautionary statement 2025	PU
03-03	GSK : completes acquisition of RAPT Therapeutics	PU
02-27	GSK plc - Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis	AQ
02-26	GSK enters agreement to acquire 35Pharma Inc.	AQ
02-25	GSK : ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen	PU
02-25	GSK : ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing	PU
02-23	Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract	BU
02-18	GSK : ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM	PU
02-18	GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows	BU
02-18	GSK plc - Exdensur approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps	AQ
02-17	GSK : Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows	PU
02-10	GSK : RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older	PU
02-05	GSK : FY 2025 results transcript	PU
02-04	Glaxo: Q4 Earnings Snapshot	AQ
02-04	GSK : Full results	PU
02-04	GSK : FY 2025 results slides	PU
02-04	GSK : FY 2025 pipeline assets and clinical trials report	PU
02-04	GSK : FY 2025 results infographic	PU